GuidelineNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2014
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.
Guideline in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic.QJM : monthly journal of the Association of Physicians · 2021Article
- Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis.Frontiers in immunology · 2020Observational
- Evaluation of serum interferons in patients with age-related macular degeneration.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2019Article
- Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis.Journal of clinical neurology (Seoul, Korea) · 2018Article
- Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway.Scientific reports · 2017Article
- Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents.Therapeutic drug monitoring · 2017Review
- Myxovirus resistance protein A (MxA) polymorphism is associated with IFNβ response in Iranian multiple sclerosis patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Article
- Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.Clinical pharmacology : advances and applications · 2017Review
- Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study.Journal of neurology · 2016Article
- Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.PloS one · 2016Article
- The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.PloS one · 2016Article
- Prevalence of neutralising antibodies to interferon-beta and clinical response in Chinese patients with relapsing multiple sclerosis.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
- Erratum issuedTroiano, Maria [corrected to Trojano, Maria]
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferon beta (IFNβ) was the first specific disease-modifying treatment licensed for relapsing-remitting multiple sclerosis, and is still one of the most commonly prescribed treatments. A strong body of evidence supports the effectiveness of IFNβ preparations in reducing the annual relapse rate, magnetic resonance (MRI) disease activity and disease progression. However, the development of binding/neutralizing antibodies (BAbs/NAbs) during treatment negatively affects clinical and MRI outcomes. Therefore, guidelines for the clinical use for the detection of NAbs in MS may result in better treatment of these patients. In October 2012, a panel of Italian neurologists from 17 MS clinics convened in Milan to review and discuss data on NAbs and their clinical relevance in the treatment of MS. In this paper, we report the panel's recommendations for the use of IFNβ Nabs detection in the early identification of IFNβ non-responsiveness and the management of patients on IFNβ treatment in Italy, according to a model of therapeutically appropriate care.
Indexed as
Identifiers
24374787What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.